Melanotan-2: Dosing Protocols

Research Dosing Disclaimer#

The dosing information below is derived from research studies and is provided for educational purposes only. Melanotan-2 is not approved for human use, and no official dosing guidelines exist.

Dose-Response Data#

We synthesized dose–response data for Melanotan-2 (Melanotan II, MT-II) across species and routes, emphasizing mg/kg dosing and observed outcomes.

Peripheral dosing (mg/kg) and outcomes

• Rats (Long–Evans), acute IP/IV/SC: Single-dose studies demonstrated clear dose–response for aversive/visceral illness and anorexia. IP 0.3–10 mg/kg and IV 0.03–1.0 mg/kg produced reductions in saccharin preference consistent with conditioned taste aversion (CTA), with significant effects at the higher IP and IV doses; SC 3–30 mg/kg produced dose-dependent CTA. The same work showed reduced food intake and body-weight loss persisting hours to days after administration. Chronic SC delivery at 1 mg/kg/day via minipump over 7 days reduced intake and body weight and supported CTA, indicating persistent aversive signaling with repeated exposure.
• Developing rat pups (Wistar), IP: A postnatal day 10–11 dose–response screen at 0.1, 3, and 10 mg/kg ip informed selection of 3 mg/kg for repeated twice-daily dosing at specific developmental windows. At 3 mg/kg, MT-II attenuated body-weight gain, reduced stomach weight (proxy for intake), and increased brown adipose UCP1 mRNA, indicating combined hypophagia and thermogenic activation. Effects were observed at P5–6, P10–11, and P15–16, demonstrating robust efficacy at 3 mg/kg with evidence of underlying brain activation (c-Fos) but no NPY mRNA change.
• Mice (C57BL/6J), IP: Systemic 10 mg/kg ip produced a profound, transient hypometabolism/hypothermia mediated by mast cells and histamine H1 receptors. Hypothermia was abolished in mast cell–deficient mice and blunted by H1 blockade; central (ICV) administration did not reproduce hypothermia, indicating a peripheral mechanism. Hypotension has also been associated with systemic dosing. This establishes a dose–linked thermoregulatory liability at 10 mg/kg ip in mice.
• Mice (C57BL/6J), IP, ethanol-intake model: Low-dose MT-II shifted the ethanol-intake dose–response. An ED20 was reported at 0.26 mg/kg ip; coadministration with naltrexone yielded synergistic suppression of binge-like ethanol intake, demonstrating pharmacological potency at sub-mg/kg levels for this behavioral endpoint.
• Prairie voles, neonatal SC: 10 mg/kg sc daily on PND1–7 produced lasting, sex-dependent social-behavioral changes (reduced juvenile play in males; facilitated adult partner preference in females), indicating developmental sensitivity at this exposure; dosing is weight-adjusted (mg/kg) and repeated daily.
• Mice (maternal immune activation model), SC continuous: Seven-day continuous systemic administration (authors empirically used ~10 mg/kg systemic exposure via minipump) rescued social-behavior deficits in MIA males; normal C57 controls exhibited significant weight loss over the subacute course, consistent with anorectic/energy-expenditure effects.

Central dosing (absolute doses and body-weight context)

• Rats, third ventricle (i3vt): Absolute doses of 0.1–1.0 nmol i3vt acutely reduced food intake (1.0 nmol reduced 48-h intake) and body weight at 24–48 h, and produced CTA, with hypothalamic and amygdalar c-Fos induction. These are absolute intracerebroventricular doses rather than mg/kg; the subjects weighed 300–400 g, which should be considered when estimating exposure per body weight.
• Rats, fourth vs lateral ventricle: Dose–response functions for MT-II administered to the fourth ventricle or lateral ventricle showed graded suppression of 2–4 h intake and 24 h intake/body weight; an antagonist produced reciprocal increases. The study supports central site dependence but reports doses as central amounts (not mg/kg). Body-weight changes tracked intake suppression, indicating mechanism via hypophagia.
• Mice, lateral ventricle: A single ICV bolus of 1 μg (≈0.036 mg/kg in a ~27 g mouse) suppressed 30-min food intake in wild type; MC3R/MC4R knockouts exhibited partial or no response, mapping anorectic efficacy to melanocortin receptors. This provides an absolute central dose with an approximate per-kg context.
• Rats, chronic ICV infusion: Continuous lateral-ventricle infusion at 0.04 μg/day or 1 μg/day for 40 days produced an initial 30–50% anorexia that waned within 2–5 days, yet body mass and adiposity remained reduced at day 40; iBAT UCP1 protein rose, consistent with increased thermogenic capacity. Doses are absolute central infusion rates; mg/kg conversion is not provided by the authors.

Cross-cutting dose–response themes and safety signals

• Anorexia and weight loss scale with dose across routes: Peripheral mg/kg dosing in rats and mice reduces intake and body weight; central absolute dosing reproduces anorexia with strong potency at sub-microgram to microgram levels. Chronic central infusion shows tachyphylaxis of anorexia but sustained body-mass reduction and thermogenic markers.
• Thermoregulatory liability in mice at high peripheral dose: 10 mg/kg ip triggers mast cell–dependent hypothermia; central MT-II does not cause hypothermia, indicating a peripheral mechanism distinct from MC4R-mediated hypermetabolism.
• Aversive effects scale with dose and route: CTA is consistently observed after higher acute peripheral doses and with chronic exposure (1 mg/kg/day) in rats, indicating a dose-related visceral malaise component that can confound intake endpoints.
• Behavioral endpoints show efficacy at low systemic doses: Ethanol-intake suppression had an ED20 near 0.26 mg/kg ip in mice, suggesting some behaviors are sensitive at sub-mg/kg levels.
• Developmental exposures at 10 mg/kg sc can have long-lasting social/behavioral effects, highlighting sensitivity of the developing brain to MT-II.

Notes on body-weight adjustments and conversions

• Where only absolute central doses are provided, we report them with body mass context. For example, 1 μg ICV in a ~27 g mouse approximates 0.036 mg/kg; rat i3vt doses were 0.1–1.0 nmol in 300–400 g animals (mass-based conversion would require MT-II molecular weight and injection volume), so we retain absolute units and indicate subject weights.

Conclusion Across species, MT-II produces dose-dependent anorexia and body-weight loss with both peripheral mg/kg and central absolute dosing, often accompanied by CTA at higher or repeated peripheral doses. Thermogenic markers (iBAT UCP1) increase with effective doses in rats, and in mice, high peripheral doses (10 mg/kg ip) cause mast cell–dependent hypothermia, a safety liability not reproduced by central dosing. Behavioral models reveal efficacy at lower mg/kg exposures (e.g., 0.26 mg/kg ip) and developmental regimens (10 mg/kg sc) yield persistent social effects. These data provide dose–response and body weight–adjusted context for MT-II use in animals across multiple endpoints.

Administration Routes#

Question and scope. Melanotan II (MT-II) is a cyclic melanocortin receptor agonist. For comparing administration routes, key pharmacokinetic (PK) endpoints include bioavailability (F), time to peak concentration (Tmax), peak concentration (Cmax), systemic exposure (AUC), and terminal half-life (t1/2). Below, we summarize route-specific PK and bioavailability, prioritizing human data when available and using closely related melanocortins as comparators where direct MT‑II data are lacking (noted explicitly).

Comparative summary by route

• Subcutaneous (SC) • Direct human MT‑II PK data were not found in the retrieved sources. As a human SC comparator within the same pharmacological class, bremelanotide (PT‑141) 1.75 mg SC showed a median Tmax ≈1 h, mean Cmax ≈72.8 ng/mL, and mean terminal t1/2 ≈2.7 h; SC administration provides effective systemic exposure (parenteral; assumed near-complete bioavailability). These values suggest that small, cyclized melanocortin peptides achieve rapid absorption and short elimination half-lives after SC dosing in humans, but they should not be assumed to equal MT‑II without direct data.

• Intravenous (IV) baseline for MT‑II (animal) • In rats given MT‑II 0.3 mg/kg IV, plasma profiles were biphasic with a rapid distribution phase (alpha half-life ≈15 min) and an elimination phase with t1/2β ≈1.5 ± 0.5 h; clearance was low relative to rat blood flows, consistent with chemical modifications that increase proteolytic stability (IV F=100%). Analytical method development supporting these measurements and mass spectrometric confirmation for MT‑II are also documented. A preliminary single-animal IV data set reported an apparent much longer terminal half-life (~61.2 h), underscoring potential inter-study variability and the need for cautious interpretation.

• Oral • No human oral PK/bioavailability data for MT‑II were found in the retrieved texts. Preformulation studies show physicochemical properties favoring membrane partitioning when unionized and indicate measurable stability in buffered media and simulated gastric matrices, suggesting feasibility for absorption; however, peptide oral delivery is generally limited by enzymolysis and permeability barriers, and the net bioavailability for MT‑II in humans remains unknown (likely low to modest without enabling technologies). Accordingly, no quantitative Tmax/Cmax/AUC/absolute F can be provided for oral MT‑II from the present evidence set.

• Intramuscular (IM) • No direct human IM PK data for MT‑II were identified in the retrieved sources. Formulation studies and depot/implant approaches for melanocortin peptides in animals suggest IM or implant delivery can substantially prolong apparent release (days to weeks), but quantitative human MT‑II IM bioavailability and PK parameters were not located here.

• Topical/transdermal (skin) • Robust human skin/transdermal PK data for MT‑II were not found in the retrieved sources. Available formulation and stability work emphasize that systemic uptake by skin would be highly formulation‑dependent and likely limited without penetration enhancers; no reliable human Cmax/Tmax/t1/2/F metrics for MT‑II via dermal routes were identified.

Supporting artifact summarizing route comparisons and evidence availability is embedded below.

Interpretation and practical implications

• SC: For melanocortin peptides, human SC dosing yields rapid absorption and short terminal half-lives on the order of hours; bremelanotide’s human data provide a reasonable class comparator while acknowledging that MT‑II may differ quantitatively.
• IV baseline (animal): Rat IV MT‑II PK indicates rapid distribution and relatively short elimination (t1/2β ≈1.5 h) in most data, though individual studies can report longer apparent terminal phases; this baseline informs expectations for parenteral routes like SC/IM where absorption kinetics may dominate early exposure.
• Oral: Physicochemical and stability profiles suggest potential for some absorption, but without human PK, oral bioavailability remains uncertain; peptide class challenges likely limit F unless specialized delivery technologies are used.
• IM and topical: Evidence gaps predominate. Animal/formulation data show prolonged exposure is achievable with depot/implant strategies for IM, but human MT‑II IM PK is not documented here; for dermal routes, no robust human PK was retrieved.

Evidence limitations

• Direct, quantitative human MT‑II PK for SC, IM, oral, or dermal routes were not retrieved; bremelanotide is used solely as a human SC comparator within the same class. Rat IV data provide systemic elimination characteristics for MT‑II but may not extrapolate directly to human values. Preformulation findings inform plausibility for oral absorption but do not establish human bioavailability.

Human-Equivalent Dosing#

Summary of methods used to translate animal doses to human‑equivalent dose (HED)

1. Body surface area (BSA) or Km method

• Definition and formula: Convert animal mg/kg to mg/m2 using the animal species’ Km, then divide by the human Km to obtain HED in mg/kg. Equivalently: HED (mg/kg) = Animal dose (mg/kg) × (Km_animal / Km_human). Km is defined as body weight (kg) divided by body surface area (m2). Example tabulated Kms include human adult ≈37, dog ≈20, rat ≈6, with typical mouse ≈3; conversion can be done directly by Km ratios. This approach underlies FDA guidance for deriving a first‑in‑human estimate from animal toxicology (NOAEL → HED) before applying a safety factor to define the MRSD.
• Practice notes: Reviews caution against simple weight‑based mg/kg extrapolation and emphasize using BSA/Km or other allometry for interspecies dose conversion; an initial human dose is frequently set as MRSD = HED/≥10 when using the NOAEL‑based “dose‑by‑factor” approach.

2. Power‑law allometry using body‑weight exponents

• Generalized formula: HED (mg/kg) = Animal dose (mg/kg) × (W_animal/W_human)^(1−b), where b is an interspecies exponent (commonly 0.75 for metabolic processes or 0.67 for surface‑area–based scaling). Practical variants include simplified exponents for dose (e.g., 0.33) when animals fall outside standard weight ranges. These schemes are presented as alternatives or complements to BSA/Km tables.

3. PK‑guided scaling and MABEL/MRSD frameworks

• Pharmacokinetically guided approaches match human exposure (e.g., AUC or Cmax) using estimated human clearance to back‑calculate a starting dose; for biologics/peptides, MABEL can be prioritized over MRSD to avoid excessive starting doses when target‑mediated disposition or receptor pharmacology yields nonlinearity. Conventional allometry can fail for protein/peptide drugs; thus, PK/PD modeling and mechanistic approaches (including PBPK) are often recommended.

4. Critiques and clarifications on BSA scaling

• A FASEB critique argues BSA‑based conversions are antiquated and may be misleading if they ignore interspecies differences in absorption, metabolism, or clearance; physiologic/PK‑based methods are encouraged. At the same time, regulatory documents have used BSA normalization as one option for FIH dose estimation, but not as a universal rule.

Evidence specific to Melanotan‑2 (MT‑II)

• Human clinical dose: Early human studies administered subcutaneous MT‑II at 0.025 mg/kg, reporting erectile and sexual motivation effects alongside dose‑related nausea. This represents an empirically derived clinical dose; the study does not show an allometric back‑calculation from animal dosing.
• Mouse preclinical dosing and PK: Adult male mice received 1 mg/kg intraperitoneal MT‑II. Plasma concentrations declined rapidly and brain concentrations were very low (brain:plasma ratios <0.01), indicating minimal CNS exposure via this route. This paper provides an animal mg/kg dose with measured exposure, enabling exposure‑matching concepts for translation.
• Rabbit preclinical dosing: Anesthetized rabbits given intravenous MT‑II at two dose levels showed dose‑related increases in cavernosal pressure; the paper cites prior human subcutaneous erection responses. No interspecies HED calculation is reported in the study.
• Overall, in the MT‑II literature we identified, explicit HED calculations from animal mg/kg doses were not presented; early human dosing appears to have been set empirically in phase I/II studies rather than explicitly scaled from animal doses using BSA/Km.

Worked example of BSA/Km scaling applied to an MT‑II animal dose (illustrative)

• Suppose a mouse dose is 1 mg/kg (ip). Using typical Km values (mouse ~3; human 37): HED ≈ 1 × (3/37) ≈ 0.081 mg/kg. For a 70‑kg adult, this corresponds to ~5.7 mg total. This back‑of‑the‑envelope HED is larger than the empirically used 0.025 mg/kg (~1.75 mg for 70 kg) in early human studies, illustrating the general caution that BSA‑based HED may not equal the optimal or tolerated human dose for a peptide; PK/PD considerations (e.g., route, bioavailability, clearance, target engagement) can lead to lower or different clinical doses.

What allometric methods have been used in the literature?

• BSA/Km scaling with tabulated Km factors to convert mg/kg across species; often embedded in NOAEL→HED→MRSD workflows for first‑in‑human dose setting.
• Power‑law allometry with exponents b ≈ 0.67 or 0.75 to relate dose across species by body weight ratios; simplified 0.33 exponent rules are sometimes used for dose when outside standard weight ranges.
• PK/exposure‑guided approaches (clearance‑based, AUC‑matching), and MABEL vs MRSD selection, especially relevant for peptides and biologics to mitigate risks from nonlinear PK/PD.
• Methodological critiques emphasize that BSA alone can mislead; physiologic, PK/PD, and PBPK methods are recommended when available.

Conclusions

• Standard practice for animal‑to‑human dose translation uses BSA (Km) scaling to estimate HED, with human Km ~37 and typical small‑animal Kms (mouse ~3, rat ~6, dog ~20). Alternative allometric formulas using body‑weight exponents (0.67–0.75) and PK‑guided exposure matching are also used. In the available MT‑II literature, human dosing (0.025 mg/kg s.c.) appears to have been chosen empirically in early clinical studies rather than by explicit HED back‑calculation from animal studies, although illustrative BSA/Km conversions can be performed. For peptides like MT‑II, PK/PD and route‑dependent bioavailability make exposure‑guided approaches preferable when data are available, and BSA estimates should be treated as rough starting points, not definitive translations.

Evidence Gaps#

• No human dose-finding studies have been completed
• Allometric scaling from animal models has inherent limitations
• Route-specific bioavailability data in humans is absent
• Optimal treatment duration has not been established

Related Reading#

• Melanotan-2 overview and research guide
• Melanotan-2 side effects profile
• Melanotan-2 research evidence